CDK4/6i, including abemaciclib, have received FDA approval for the treatment of advanced HR+, HER2− metastatic breast cancer but are also under investigation in multiple preclinical and clinical studies for the treatment of other solid tumors, including triple-negative breast cancer (TNBC) (Hu et al, 2021). Here, CDK4 is linked to triple-negative breast carcinoma.